产品说明
应用
Clinically useful anticancer agent.
生化/生理作用
Initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-beta (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM) (1). Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms (2). Inhibits activation of MAPK pathway and ERK phosphorylation (3). Induces caspase-independent apoptosis in melanoma cells (4).
重悬
Formulated as a lyophilized powder. May be dissolved in DMSO (200 mg/mL) or Ethanol (3 mg/mL).
储存及稳定性
Store desiccated as supplied at -20℃ for up to 2 years. Store solutions at -20℃ for up to 1 month.
产品性质
| 测定 | >95% (TLC) |
| 形式 | lyophilized powder |
| 分子量 | ~464.8 |
| 运输 | ambient |
| 储存温度 | −20℃ |
安全信息
| 象形图 |   |
| 警示用语： | Danger |
| 危险声明 | H360FD - H362 - H372 - H410 |
| 预防措施声明 | P202 - P260 - P263 - P264 - P273 - P308 + P313 |
| 危险分类 | Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1 |
| 储存分类代码 | 6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
